Notice2022-11401

National Institute on Drug Abuse; Notice of Closed Meetings

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
May 27, 2022

Issuing agencies

Health and Human Services DepartmentNational Institutes of Health

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 103 (Friday, May 27, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 103 (Friday, May 27, 2022)]
[Notices]
[Page 32178]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-11401]



[[Page 32178]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; HEAL Initiative: Data and Methods to Address Urgent 
Needs to Stem the Opioid Epidemic.
    Date: June 27-28, 2022.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health National, Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Jenny Raye Browning, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
3WFN, MSC 6021, Bethesda, MD 20892, (301) 443-4577, 
<a href="/cdn-cgi/l/email-protection#6f050a010116410d1d0018010601082f01060741080019"><span class="__cf_email__" data-cfemail="365c5358584f1854445941585f585176585f5e18515940">[email&#160;protected]</span></a>.

    Name of Committee: National Institute on Drug Abuse Initial 
Review Group; Medication Development Research Study Section.
    Date: July 13, 2022.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer, 
Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 
North Stonestreet Avenue, 3WFN, MSC 6021, Bethesda, MD 20892, 301-
443-4577, <a href="/cdn-cgi/l/email-protection#036d627a62717331436070712d6d6a6b2d646c75"><span class="__cf_email__" data-cfemail="90fef1e9f1e2e0a2d0f3e3e2befef9f8bef7ffe6">[email&#160;protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: May 23, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-11401 Filed 5-26-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on May 27, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.